|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
CA2872136C
(en)
|
2002-07-18 |
2017-06-20 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
|
AU2004242614B2
(en)
|
2003-05-30 |
2011-09-22 |
Merus N.V. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
AU2007305443B2
(en)
|
2006-09-29 |
2012-08-23 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
WO2008076904A1
(en)
|
2006-12-14 |
2008-06-26 |
Aileron Therapeutics, Inc. |
Bis-sulfhydryl macrocyclization systems
|
|
EP2564862B1
(en)
|
2007-02-23 |
2017-08-02 |
Aileron Therapeutics, Inc. |
Substituted amino acids for preparing triazole linked macrocyclic peptides
|
|
ES2430067T3
(es)
|
2007-03-28 |
2013-11-18 |
President And Fellows Of Harvard College |
Polipéptidos cosidos
|
|
MX2009010282A
(es)
|
2007-03-29 |
2009-10-12 |
Genmab As |
Anticuerpos biespecificos y metodos para su produccion.
|
|
ES2566957T3
(es)
|
2007-09-26 |
2016-04-18 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SI2235064T1
(sl)
*
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
CN102076355B
(zh)
|
2008-04-29 |
2014-05-07 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
TW201008580A
(en)
|
2008-06-03 |
2010-03-01 |
Abbott Lab |
Dual variable domain immunoglobulin and uses thereof
|
|
KR20220002710A
(ko)
|
2008-06-26 |
2022-01-06 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
|
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
|
BRPI1006139A2
(pt)
|
2009-01-14 |
2017-05-30 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos
|
|
EP2382228B2
(en)
|
2009-01-21 |
2026-01-07 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
WO2010084197A1
(en)
*
|
2009-01-26 |
2010-07-29 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
CN102365297B
(zh)
|
2009-03-25 |
2014-10-29 |
霍夫曼-拉罗奇有限公司 |
新型抗-α5β1抗体及其应用
|
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
|
AU2013203859B2
(en)
*
|
2009-04-27 |
2016-09-08 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
WO2010129304A2
(en)
*
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
CA2766220C
(en)
|
2009-06-26 |
2021-02-09 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
AU2010270844A1
(en)
|
2009-07-08 |
2011-12-22 |
Amgen Inc. |
Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering
|
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
WO2011028952A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
CN102712675A
(zh)
|
2009-09-22 |
2012-10-03 |
爱勒让治疗公司 |
拟肽大环化合物
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
EP3072526B1
(en)
|
2009-10-16 |
2018-09-26 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2781539C
(en)
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
|
HUE029257T2
(en)
*
|
2009-12-29 |
2017-02-28 |
Aptevo Res And Dev Llc |
Heterodimer binding proteins and their use
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
PL2505654T5
(pl)
|
2010-02-08 |
2020-11-30 |
Regeneron Pharmaceuticals, Inc. |
Mysz ze wspólnym łańcuchem lekkim
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
WO2011127418A1
(en)
|
2010-04-09 |
2011-10-13 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
JP2019048814A
(ja)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
AU2016219622A1
(en)
*
|
2010-04-20 |
2016-09-15 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
ES2989108T3
(es)
*
|
2010-04-20 |
2024-11-25 |
Genmab As |
Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
|
|
TW201742925A
(zh)
|
2010-04-23 |
2017-12-16 |
建南德克公司 |
異多聚體蛋白質之製造
|
|
US9527926B2
(en)
*
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CA2800785C
(en)
|
2010-05-27 |
2019-09-24 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
BR112012027995A2
(pt)
|
2010-06-18 |
2017-01-10 |
Genentech Inc |
anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
JP2013539962A
(ja)
|
2010-07-09 |
2013-10-31 |
ジェネンテック， インコーポレイテッド |
抗ニューロピリン抗体及び使用方法
|
|
CN103180737A
(zh)
|
2010-07-19 |
2013-06-26 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
WO2012010549A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2600898A1
(en)
|
2010-08-05 |
2013-06-12 |
F.Hoffmann-La Roche Ag |
Anti-mhc antibody anti-viral cytokine fusion protein
|
|
CN103168049B
(zh)
|
2010-08-13 |
2015-10-07 |
罗切格利卡特公司 |
抗生腱蛋白-c a2抗体及使用方法
|
|
KR101780131B1
(ko)
|
2010-08-13 |
2017-09-19 |
로슈 글리카트 아게 |
항-fap 항체 및 이의 사용 방법
|
|
DK2603600T3
(da)
|
2010-08-13 |
2019-03-04 |
Aileron Therapeutics Inc |
Peptidomimetiske makrocyklusser
|
|
CN103080132B
(zh)
|
2010-08-25 |
2016-06-08 |
弗·哈夫曼-拉罗切有限公司 |
抗il-18r1的抗体及其用途
|
|
EP2608803A4
(en)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
RU2013114360A
(ru)
|
2010-08-31 |
2014-10-10 |
Дженентек, Инк. |
Биомаркеры и способы лечения
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
AU2011325833C1
(en)
*
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
EP3176184B1
(en)
|
2010-11-10 |
2020-02-19 |
F. Hoffmann-La Roche AG |
Anti-bace1 antibodies for neural disease immunotherapy
|
|
PH12013500974A1
(en)
|
2010-11-17 |
2013-07-08 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
EA034333B1
(ru)
|
2010-11-30 |
2020-01-29 |
Дженентек, Инк. |
Варианты антитела для переноса соединения через гематоэнцефалический барьер
|
|
MX349057B
(es)
|
2010-11-30 |
2017-07-07 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico que induce citotoxicidad.
|
|
TWI732259B
(zh)
|
2010-12-16 |
2021-07-01 |
美商建南德克公司 |
關於th2抑制作用之診斷及治療
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
SG191219A1
(en)
|
2010-12-22 |
2013-07-31 |
Genentech Inc |
Anti-pcsk9 antibodies and methods of use
|
|
KR101913448B1
(ko)
|
2011-02-04 |
2018-10-30 |
제넨테크, 인크. |
Fc 변이체 및 그의 생산 방법
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
TWI666027B
(zh)
|
2011-02-10 |
2019-07-21 |
羅齊克雷雅公司 |
突變介白素-２多肽
|
|
WO2012116927A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
|
ES2676878T3
(es)
|
2011-03-03 |
2018-07-25 |
Zymeworks Inc. |
Diseño de armazón de heteromultímero multivalente y constructos
|
|
CA2830254C
(en)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Fc variants
|
|
EP2688909A2
(en)
|
2011-03-25 |
2014-01-29 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
KR101614195B1
(ko)
|
2011-03-29 |
2016-04-20 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
|
US10752664B2
(en)
|
2011-04-08 |
2020-08-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
|
DK2697257T3
(en)
|
2011-04-13 |
2017-01-30 |
Bristol Myers Squibb Co |
FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
|
|
WO2012143523A1
(en)
*
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
RU2013150331A
(ru)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
ES2567276T3
(es)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
|
|
BR112013026266A2
(pt)
|
2011-05-16 |
2020-11-10 |
Genentech, Inc |
método de tratamento, anticorpos isolado e anti-fgfr1, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de diabetes em um indivíduo
|
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
|
RU2641256C2
(ru)
*
|
2011-06-30 |
2018-01-16 |
Чугаи Сейяку Кабусики Кайся |
Гетеродимеризованный полипептид
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
WO2013010840A2
(en)
|
2011-07-18 |
2013-01-24 |
Arts Biologics A/S |
Long acting biologically active luteinizing hormone (lh) compound
|
|
EP2736925A2
(en)
*
|
2011-07-27 |
2014-06-04 |
Glaxo Group Limited |
Anti-vegf single variable domains fused to fc domains
|
|
WO2013022782A1
(en)
|
2011-08-05 |
2013-02-14 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
CA2844540C
(en)
|
2011-08-23 |
2018-10-16 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
RS56879B1
(sr)
|
2011-08-23 |
2018-04-30 |
Roche Glycart Ag |
Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
|
|
CN103890006A
(zh)
|
2011-08-23 |
2014-06-25 |
罗切格利卡特公司 |
抗mcsp抗体
|
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
JP2014534949A
(ja)
|
2011-09-19 |
2014-12-25 |
ジェネンテック， インコーポレイテッド |
Ｃ−ｍｅｔアンタゴニストおよびｂ−ｒａｆアンタゴニストを含む組合せ処置
|
|
MY173865A
(en)
|
2011-09-22 |
2020-02-25 |
Amgen Inc |
Cd27l antigen binding proteins
|
|
EP2758073B1
(en)
|
2011-09-23 |
2018-10-31 |
OncoMed Pharmaceuticals, Inc. |
Vegf/dll4 binding agents and uses thereof
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013052155A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
MX359384B
(es)
|
2011-10-11 |
2018-09-25 |
Genentech Inc |
Conjunto mejorado de anticuerpos bisespecificos.
|
|
HUE039133T2
(hu)
|
2011-10-14 |
2018-12-28 |
Hoffmann La Roche |
Anti-HtrA1 antitestek és felhasználási módszerek
|
|
EP2766000A2
(en)
|
2011-10-15 |
2014-08-20 |
F.Hoffmann-La Roche Ag |
Scd1 antagonists for treating cancer
|
|
CA2852468A1
(en)
|
2011-10-18 |
2013-04-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocyles
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
SG10201805291TA
(en)
|
2011-10-27 |
2018-08-30 |
Genmab As |
Production of heterodimeric proteins
|
|
AU2012328980A1
(en)
|
2011-10-28 |
2014-04-24 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
ES2732712T3
(es)
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
US20130142809A1
(en)
|
2011-11-23 |
2013-06-06 |
Andrew A. Welcher |
METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
|
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
WO2013096221A1
(en)
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
HRP20200744T1
(hr)
|
2011-12-22 |
2020-07-24 |
F. Hoffmann - La Roche Ag |
Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
|
|
EP2794662A1
(en)
|
2011-12-22 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
|
WO2013092743A2
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
UY34558A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
|
|
CN102558355B
(zh)
*
|
2011-12-31 |
2015-02-25 |
苏州康宁杰瑞生物科技有限公司 |
基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
|
|
EP2804629A1
(en)
|
2012-01-18 |
2014-11-26 |
Genentech, Inc. |
Anti-lrp5 antibodies and methods of use
|
|
US20130183294A1
(en)
|
2012-01-18 |
2013-07-18 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
BR112014018575A2
(pt)
*
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
|
EP2809682B1
(en)
|
2012-02-03 |
2020-04-08 |
F.Hoffmann-La Roche Ag |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
|
SG10201704849PA
(en)
|
2012-02-09 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
|
CN104125852B9
(zh)
|
2012-02-15 |
2017-05-17 |
弗·哈夫曼-拉罗切有限公司 |
基于Fc‑受体的亲和色谱
|
|
SG10201606775YA
(en)
|
2012-02-15 |
2016-10-28 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
|
HK1205454A1
(en)
|
2012-02-15 |
2015-12-18 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ３阻害剤に関する診断及び治療
|
|
US9550819B2
(en)
|
2012-03-27 |
2017-01-24 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
KR101674784B1
(ko)
|
2012-04-05 |
2016-11-09 |
에프. 호프만-라 로슈 아게 |
인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
|
|
CN114163530B
(zh)
*
|
2012-04-20 |
2025-04-29 |
美勒斯公司 |
用于产生免疫球蛋白样分子的方法和手段
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
WO2013166594A1
(en)
*
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
WO2013166604A1
(en)
*
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Single-arm monovalent antibody constructs and uses thereof
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
|
EP3594239B1
(en)
|
2012-05-21 |
2024-10-30 |
F. Hoffmann-La Roche AG |
Methods for improving safety of blood-brain barrier transport
|
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
|
WO2013188855A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104619722B
(zh)
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
ES2604012T3
(es)
|
2012-07-04 |
2017-03-02 |
F. Hoffmann-La Roche Ag |
Conjugados de antígeno-anticuerpo unidos covalentemente
|
|
RU2630664C2
(ru)
|
2012-07-04 |
2017-09-11 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к теофиллину и способы их применения
|
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
|
CA3188124A1
(en)
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
US20140030282A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates
|
|
KR20150027829A
(ko)
|
2012-07-09 |
2015-03-12 |
제넨테크, 인크. |
항-cd22 항체를 포함하는 면역접합체
|
|
SG11201500093TA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd79b antibodies
|
|
TW201408696A
(zh)
|
2012-07-09 |
2014-03-01 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
WO2014011988A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
|
WO2014012085A2
(en)
*
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
|
SMT202100621T1
(it)
|
2012-07-13 |
2022-01-10 |
Roche Glycart Ag |
Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
|
|
CA2878640C
(en)
|
2012-07-13 |
2023-10-24 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
MX366178B
(es)
|
2012-07-19 |
2019-07-01 |
Amgen Inc |
Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
|
|
CN102851338A
(zh)
*
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
|
PL3434695T3
(pl)
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Ulepszona immunoterapia
|
|
MX2015001678A
(es)
|
2012-08-09 |
2015-08-14 |
Roche Glycart Ag |
Anticuerpos asgpr y sus usos.
|
|
AU2013306700B2
(en)
|
2012-08-24 |
2019-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIb-specific Fc region variant
|
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスＦｃγＲＩＩ特異的Ｆｃ抗体
|
|
EP2892558B1
(en)
|
2012-09-07 |
2019-04-10 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
CA2886036A1
(en)
|
2012-09-25 |
2014-04-03 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
SG10201705787VA
(en)
|
2012-09-27 |
2017-08-30 |
Merus Nv |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
|
EP2904093B1
(en)
|
2012-10-03 |
2019-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
PROCESS AND MONITOR THE TREATMENT WITH A DLL4 ANTAGONIST
|
|
KR20190096459A
(ko)
|
2012-11-01 |
2019-08-19 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
CA2887285A1
(en)
|
2012-11-01 |
2014-05-08 |
Aileron Therapeutics, Inc. |
Disubstituted amino acids and methods of preparation and use thereof
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
ES2949394T3
(es)
|
2012-11-05 |
2023-09-28 |
Found Medicine Inc |
Moléculas de fusión novedosas y usos de las mismas
|
|
CN104797599A
(zh)
|
2012-11-05 |
2015-07-22 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
MA38176A1
(fr)
|
2012-11-13 |
2017-06-30 |
Genentech Inc |
Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
|
|
WO2014079000A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
UY35148A
(es)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
JP6385357B2
(ja)
*
|
2012-11-27 |
2018-09-05 |
アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ |
抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
|
|
MX385344B
(es)
|
2012-11-28 |
2025-03-18 |
Zymeworks Bc Inc |
Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
|
EA201500741A1
(ru)
|
2013-01-10 |
2016-01-29 |
Генмаб Б.В. |
ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10738132B2
(en)
|
2013-01-14 |
2020-08-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
|
CA2899170C
(en)
|
2013-01-30 |
2022-08-02 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use in treating metabolic disorders
|
|
HK1218930A1
(zh)
*
|
2013-02-08 |
2017-03-17 |
Abbvie Stemcentrx Llc |
新型多特异性结构
|
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
ES2870802T3
(es)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
HUE067221T2
(hu)
*
|
2013-02-15 |
2024-10-28 |
R Pharm Int Llc |
IL-1béta inhibitor készítmény és annak alkalmazása
|
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
|
EP2961772A1
(en)
|
2013-02-26 |
2016-01-06 |
Roche Glycart AG |
Anti-mcsp antibodies
|
|
MX2015010350A
(es)
|
2013-02-26 |
2015-10-29 |
Roche Glycart Ag |
Moleculas de union a antigeno biespecificas que activan la celula t.
|
|
EP2961771B1
(en)
|
2013-02-26 |
2020-01-01 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules specific to cd3 and cea
|
|
HK1211299A1
(en)
|
2013-02-26 |
2016-05-20 |
罗切格利卡特公司 |
Bispecific t cell activating antigen binding molecules
|
|
JP2016510755A
(ja)
|
2013-03-06 |
2016-04-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
|
|
WO2014138364A2
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
EP2975061A4
(en)
*
|
2013-03-13 |
2017-03-01 |
Ibentrus Inc. |
Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
CA2903480A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
AU2014235453A1
(en)
|
2013-03-15 |
2015-10-08 |
Genentech, Inc. |
Biomarkers and methods of treating PD-1 and PD-L1 related conditions
|
|
CN111138543B
(zh)
*
|
2013-03-15 |
2024-06-11 |
Xencor股份有限公司 |
异二聚体蛋白
|
|
AU2014236815B2
(en)
|
2013-03-15 |
2019-04-04 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR20150128849A
(ko)
|
2013-03-15 |
2015-11-18 |
얀센 바이오테크 인코포레이티드 |
인터페론 알파 및 오메가 항체 길항제
|
|
JP2016517441A
(ja)
|
2013-03-15 |
2016-06-16 |
ジェネンテック， インコーポレイテッド |
抗ＣＲＴｈ２抗体及び使用方法
|
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
MX357011B
(es)
|
2013-03-15 |
2018-06-22 |
Amgen Inc |
Anticuerpos biespecificos heterodimericos.
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
|
EP2976361B1
(en)
|
2013-03-18 |
2018-07-18 |
BiocerOX Products B.V. |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Ｆｃ領域改変体
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
CN118561989A
(zh)
|
2013-04-29 |
2024-08-30 |
豪夫迈·罗氏有限公司 |
Fc-受体结合的修饰的非对称抗体及使用方法
|
|
TWI653243B
(zh)
|
2013-04-29 |
2019-03-11 |
赫孚孟拉羅股份公司 |
遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途
|
|
HK1213578A1
(zh)
|
2013-04-29 |
2016-07-08 |
豪夫迈‧罗氏有限公司 |
结合人fcrn的修饰的抗体和使用方法
|
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
|
KR101882366B1
(ko)
|
2013-05-30 |
2018-07-30 |
키닉사 파마슈티컬스, 리미티드 |
온코스타틴 m 수용체 항원 결합 단백질
|
|
DK3016681T5
(da)
|
2013-07-05 |
2020-05-04 |
Genmab As |
Humaniserede eller kimære CD3-antistoffer
|
|
MX369152B
(es)
|
2013-07-31 |
2019-10-30 |
Amgen Inc |
Construcciones del factor de diferenciación de crecimiento 15 (gdf-15).
|
|
AU2014332458B2
(en)
*
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
|
JP2016537399A
(ja)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
抗ｌｇｒ５抗体を使用する方法
|
|
EP3049440B1
(en)
|
2013-09-25 |
2020-03-25 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
SG10201803449VA
(en)
*
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
|
KR20160044060A
(ko)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
|
EP3055328A1
(en)
|
2013-10-11 |
2016-08-17 |
F. Hoffmann-La Roche AG |
Nsp4 inhibitors and methods of use
|
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
SG11201603127WA
(en)
|
2013-10-23 |
2016-05-30 |
Genentech Inc |
Methods of diagnosing and treating eosinophilic disorders
|
|
SI3065774T1
(sl)
|
2013-11-06 |
2021-11-30 |
Janssen Biotech, Inc. |
Protitelesa proti CCL17
|
|
US10273303B2
(en)
|
2013-11-13 |
2019-04-30 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
|
SI3071597T1
(sl)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti alfa-sinukleinska protitelesa in postopki uporabe
|
|
WO2015077891A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
HRP20200384T1
(hr)
|
2013-12-20 |
2020-06-12 |
F. Hoffmann - La Roche Ag |
Humanizirana anti-tau(ps422) protutijela i načini uporabe
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
SI3712174T1
(sl)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Protitelesa in delci proti VISTA
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10561737B2
(en)
|
2014-01-03 |
2020-02-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
KR102278979B1
(ko)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
|
|
JP6521464B2
(ja)
|
2014-01-03 |
2019-05-29 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
|
|
RU2694659C2
(ru)
|
2014-01-06 |
2019-07-16 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные модули-переносчики через гематоэнцефалический барьер
|
|
AU2014377106B2
(en)
|
2014-01-08 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
CN105916880B
(zh)
|
2014-01-15 |
2020-01-17 |
豪夫迈·罗氏有限公司 |
具有改善的蛋白A结合作用的Fc区变体
|
|
CA2931986A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
KR20160111469A
(ko)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
항-steap1 항체 및 면역접합체를 사용하는 방법
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
BR112016018170A2
(pt)
|
2014-02-08 |
2018-02-20 |
Genentech, Inc. |
métodos para tratar doença de alzheimer
|
|
CN106456729A
(zh)
|
2014-02-08 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
治疗阿尔茨海默氏病的方法
|
|
EA201691610A8
(ru)
|
2014-02-12 |
2018-05-31 |
Дженентек, Инк. |
Анти-jagged1 антитела и способы применения
|
|
CR20160379A
(es)
|
2014-02-21 |
2016-10-07 |
Genentech Inc |
Anticuerpos biespecificos anti-il 13/il-17 y sus usos
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
ES2816624T3
(es)
|
2014-02-28 |
2021-04-05 |
Merus Nv |
Anticuerpos que se unen a EGFR y ERBB3
|
|
SG11201607104RA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibody that binds erbb-2 and erbb-3
|
|
LT3116909T
(lt)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
Antikūno molekulės prieš lag-3 ir jų panaudojimas
|
|
AU2015229035B2
(en)
|
2014-03-14 |
2021-08-05 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
KR102846903B1
(ko)
|
2014-03-21 |
2025-08-20 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
WO2015148531A1
(en)
|
2014-03-24 |
2015-10-01 |
Genentech, Inc. |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
US12180264B2
(en)
|
2014-03-24 |
2024-12-31 |
R-Pharm Overseas, Inc. |
IL1-R1 derived inhibitor of IL-1β and use thereof
|
|
LT3122781T
(lt)
|
2014-03-28 |
2020-03-25 |
Xencor, Inc. |
Bispecifiniai antikūnai, kurie jungiasi prie cd38 ir cd3
|
|
EP3126394B1
(en)
|
2014-03-31 |
2019-10-30 |
F.Hoffmann-La Roche Ag |
Anti-ox40 antibodies and methods of use
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
US20170022291A1
(en)
|
2014-04-01 |
2017-01-26 |
Adimab, Llc |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
UA117289C2
(uk)
*
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
CN106164288A
(zh)
|
2014-04-02 |
2016-11-23 |
豪夫迈·罗氏有限公司 |
检测多特异性抗体轻链错配的方法
|
|
MY194892A
(en)
|
2014-04-07 |
2022-12-22 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
|
WO2015160940A1
(en)
*
|
2014-04-15 |
2015-10-22 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
ES2962694T3
(es)
|
2014-05-02 |
2024-03-20 |
Momenta Pharmaceuticals Inc |
Composiciones y procedimientos relacionados con construcciones de Fc manipuladas
|
|
HRP20231139T1
(hr)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
|
|
CN106459954A
(zh)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
|
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
|
EP3143043B1
(en)
*
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
CN106661622B
(zh)
|
2014-05-23 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
Mit生物标志物和使用它们的方法
|
|
HK1231490A1
(zh)
|
2014-05-28 |
2017-12-22 |
Zymeworks, Inc. |
修饰的抗原结合多肽构建体及其用途
|
|
WO2015187977A1
(en)
|
2014-06-04 |
2015-12-10 |
Acceleron Pharma, Inc. |
Methods and compositions for treatment of disorders with follistatin polypeptides
|
|
US10010498B2
(en)
|
2014-06-04 |
2018-07-03 |
Acceleron Pharma Inc. |
Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
CA2949982A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
MX384037B
(es)
|
2014-06-26 |
2025-03-14 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
HRP20192243T1
(hr)
|
2014-07-03 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Polipeptidni ekspresijski sustavi
|
|
WO2016005545A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
PT3169706T
(pt)
|
2014-07-11 |
2020-03-13 |
Genmab As |
Anticorpos que se ligam a axl
|
|
RU2017103289A
(ru)
|
2014-07-11 |
2018-08-14 |
Дженентек, Инк. |
Ингибирование пути notch
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
US9777073B2
(en)
*
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
EP3172237A2
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6744292B2
(ja)
*
|
2014-07-29 |
2020-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
SG11201700378PA
(en)
|
2014-07-30 |
2017-02-27 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
PE20170263A1
(es)
|
2014-08-04 |
2017-03-30 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
TW202140557A
(zh)
|
2014-08-19 |
2021-11-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
MX2017002605A
(es)
|
2014-08-28 |
2017-05-19 |
Bioatla Llc |
Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
|
|
CA2959786A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
MA40608A
(fr)
|
2014-09-09 |
2016-03-17 |
Janssen Biotech Inc |
Polythérapies avec des anticorps anti-cd38
|
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
PE20170935A1
(es)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados
|
|
BR112017004802A2
(pt)
|
2014-09-12 |
2017-12-12 |
Genentech Inc |
anticorpos anti-cll-1 e imunoconjugados
|
|
TW201620938A
(zh)
|
2014-09-15 |
2016-06-16 |
安美基公司 |
雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
|
|
MX2017003645A
(es)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
|
|
BR112017004953A2
(pt)
|
2014-09-17 |
2017-12-05 |
Genentech Inc |
imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
|
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
|
JP2017533889A
(ja)
|
2014-09-24 |
2017-11-16 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ペプチド模倣大環状分子およびその使用
|
|
SG10201902598VA
(en)
|
2014-09-24 |
2019-04-29 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and formulations thereof
|
|
WO2016046778A2
(en)
|
2014-09-25 |
2016-03-31 |
Amgen Inc |
Protease-activatable bispecific proteins
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
JP6877339B2
(ja)
|
2014-10-14 |
2021-05-26 |
ノバルティス アーゲー |
Ｐｄ−ｌ１に対する抗体分子およびその使用
|
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
|
CN107530419B
(zh)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
治疗疾病的组合疗法
|
|
DK3212226T3
(da)
|
2014-10-31 |
2020-06-15 |
Ngm Biopharmaceuticals Inc |
Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
|
|
US20170258835A1
(en)
|
2014-10-31 |
2017-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified t cells
|
|
MX2017005750A
(es)
|
2014-11-03 |
2017-12-15 |
Genentech Inc |
Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
|
|
EP3215637B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
AR102522A1
(es)
|
2014-11-06 |
2017-03-08 |
Hoffmann La Roche |
Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
RU2714116C2
(ru)
|
2014-11-06 |
2020-02-11 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
|
BR112017009728A2
(pt)
|
2014-11-10 |
2018-02-06 |
Genentech, Inc. |
anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
|
|
DK3489256T3
(da)
|
2014-11-14 |
2021-05-25 |
Hoffmann La Roche |
Antigenbindende molekyler omfattende en TNF-familieligandtrimer
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CA2968162A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
Common light chains and methods of use
|
|
DK3221356T3
(da)
|
2014-11-20 |
2020-11-02 |
Hoffmann La Roche |
T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
TN2017000223A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
IL252467B
(en)
|
2014-11-26 |
2022-06-01 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
CA2969717A1
(en)
|
2014-12-04 |
2016-06-09 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
|
PT3227336T
(pt)
|
2014-12-05 |
2019-09-09 |
Hoffmann La Roche |
Anticorpos anti-cd79b e métodos de utilização
|
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
|
CN107207591A
(zh)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
血脑屏障受体抗体及使用方法
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
CN107002114A
(zh)
|
2014-12-18 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
用于确定cdc引发抗体的测定试验和方法
|
|
WO2016097300A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
JP6227191B1
(ja)
|
2014-12-19 |
2017-11-08 |
中外製薬株式会社 |
抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
|
|
US9765135B2
(en)
|
2014-12-19 |
2017-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN110658340B
(zh)
*
|
2015-01-08 |
2023-10-31 |
苏州康宁杰瑞生物科技有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
|
KR102663073B1
(ko)
|
2015-01-08 |
2024-05-07 |
젠맵 에이/에스 |
Cd3 및 cd20에 대항한 이중특이적 항체
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
CA3248123A1
(en)
|
2015-01-31 |
2025-11-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
|
CN114773470A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
WO2016141110A1
(en)
|
2015-03-03 |
2016-09-09 |
Schlumberger Technology Corporation |
Multi-mode acoustic tool and method
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
SG11201707186YA
(en)
|
2015-03-06 |
2017-10-30 |
Genentech Inc |
Ultrapurified dsba and dsbc and methods of making and using the same
|
|
MX2017011486A
(es)
|
2015-03-16 |
2018-06-15 |
Genentech Inc |
Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
JP2018516844A
(ja)
|
2015-03-20 |
2018-06-28 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ペプチド模倣大環状分子およびその使用
|
|
JP2018510637A
(ja)
*
|
2015-03-26 |
2018-04-19 |
アクセルロン ファーマ， インコーポレイテッド |
フォリスタチン関連融合タンパク質およびその使用
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
WO2016161390A1
(en)
|
2015-04-03 |
2016-10-06 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
|
CN114736307A
(zh)
|
2015-04-06 |
2022-07-12 |
阿塞勒隆制药公司 |
TGF-β超家族I型和II型受体异多聚体及其用途
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
JP6810702B2
(ja)
|
2015-04-06 |
2021-01-06 |
アクセルロン ファーマ インコーポレイテッド |
シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
|
|
EP3280736A1
(en)
|
2015-04-07 |
2018-02-14 |
F. Hoffmann-La Roche AG |
Antigen binding complex having agonistic activity and methods of use
|
|
CA2981851A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
CN108472360B
(zh)
|
2015-04-10 |
2023-01-17 |
阿迪马布有限责任公司 |
从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法
|
|
WO2016166348A1
(en)
|
2015-04-17 |
2016-10-20 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
|
JP6952605B2
(ja)
|
2015-04-24 |
2021-10-20 |
ジェネンテック， インコーポレイテッド |
多特異性抗原結合タンパク質
|
|
EP3294771A1
(en)
|
2015-05-11 |
2018-03-21 |
H. Hoffnabb-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
|
HRP20201900T4
(hr)
|
2015-05-12 |
2024-06-07 |
F. Hoffmann - La Roche Ag |
Terapeutski i dijagnostički postupci kod raka
|
|
WO2016187546A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
|
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
|
HK1250723A1
(zh)
|
2015-05-29 |
2019-01-11 |
F. Hoffmann-La Roche Ag |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
TWI827405B
(zh)
|
2015-06-05 |
2023-12-21 |
美商建南德克公司 |
抗-ｔａｕ抗體及使用方法
|
|
CA2985483A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
JP2018524295A
(ja)
|
2015-06-15 |
2018-08-30 |
ジェネンテック， インコーポレイテッド |
抗体及び免疫複合体
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
HUE063270T2
(hu)
|
2015-06-16 |
2024-01-28 |
Hoffmann La Roche |
Az FcRH5 elleni humanizált és affinitásérett antitestek és alkalmazási eljárások
|
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
|
US10668149B2
(en)
|
2015-06-22 |
2020-06-02 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
EP3313881A1
(en)
|
2015-06-23 |
2018-05-02 |
Innate Pharma |
Multispecific nk engager proteins
|
|
CN107921120A
(zh)
|
2015-06-24 |
2018-04-17 |
詹森生物科技公司 |
用特异性结合cd38的抗体免疫调节和治疗实体瘤
|
|
CN113929779B
(zh)
|
2015-06-24 |
2025-02-25 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
|
WO2016207717A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
WO2016207091A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
|
EP3314255B1
(en)
|
2015-06-25 |
2019-07-31 |
H. Hoffnabb-La Roche Ag |
Cell based assay for determining antibody or ligand binding and function
|
|
ES2878316T3
(es)
|
2015-06-29 |
2021-11-18 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
|
|
US20170029520A1
(en)
|
2015-06-29 |
2017-02-02 |
Genentech, Inc. |
Compositions and methods for use in organ transplantation
|
|
US10059741B2
(en)
|
2015-07-01 |
2018-08-28 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
EA201890028A1
(ru)
|
2015-07-10 |
2018-08-31 |
Мерус Н.В. |
Антитело, связывающее cd3 человека
|
|
CN114989302B
(zh)
|
2015-07-15 |
2025-08-05 |
根马布股份公司 |
人源化或嵌合cd3抗体
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
SG10201906059VA
(en)
|
2015-07-30 |
2019-08-27 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
|
MX2018001522A
(es)
|
2015-08-05 |
2018-03-15 |
Janssen Biotech Inc |
Anticuerpos anti-cd154 y metodos de uso de estos.
|
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
|
GEP20217326B
(en)
|
2015-08-07 |
2021-11-25 |
Alx Oncology Inc |
Constructs having a sirp-alpha domain or variant thereof
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
ES2995985T3
(en)
|
2015-08-13 |
2025-02-11 |
Amgen Inc |
Charged depth filtration of antigen-binding proteins
|
|
BR112017026543A2
(pt)
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
plataforma de anticorpo multiespecífico e métodos relacionados
|
|
WO2017040324A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
WO2017040195A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
EP3347051A4
(en)
|
2015-09-10 |
2019-04-24 |
Affigen, Inc. |
SEQUENCING SELECTING TUMOR THEROSTICAS
|
|
EP3347372A4
(en)
|
2015-09-10 |
2019-09-04 |
Aileron Therapeutics, Inc. |
PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
|
|
JP6932700B2
(ja)
|
2015-09-15 |
2021-09-08 |
アムジエン・インコーポレーテツド |
４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
|
|
CN108271372B
(zh)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
JP6967003B2
(ja)
|
2015-09-23 |
2021-11-17 |
メレオ バイオファーマ ５ インコーポレイテッド |
がんの処置のための方法および組成物
|
|
CA2992602A1
(en)
|
2015-09-23 |
2017-03-30 |
Genentech, Inc. |
Optimized variants of anti-vegf antibodies
|
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
|
NZ739750A
(en)
|
2015-09-25 |
2019-11-29 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
JP7628764B2
(ja)
|
2015-09-29 |
2025-02-12 |
アムジエン・インコーポレーテツド |
Ａｓｇｒ阻害剤
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055539A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
|
EP3356403A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
KR102072317B1
(ko)
|
2015-10-02 |
2020-01-31 |
에프. 호프만-라 로슈 아게 |
항-pd1 항체 및 사용 방법
|
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
JP2018533930A
(ja)
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
WO2017055391A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
MY193013A
(en)
|
2015-10-07 |
2022-09-22 |
Hoffmann La Roche |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
|
EP4524161A3
(en)
|
2015-10-08 |
2025-06-04 |
Zymeworks BC Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
HRP20210483T1
(hr)
|
2015-10-23 |
2021-07-09 |
Merus N.V. |
Vezujuće molekule koje inhibiraju rast raka
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
EP3368568B1
(en)
|
2015-10-29 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
|
EP3368578B1
(en)
|
2015-10-30 |
2021-03-17 |
H. Hoffnabb-La Roche Ag |
Anti-htra1 antibodies and methods of use thereof
|
|
SMT202100192T1
(it)
|
2015-11-03 |
2021-05-07 |
Janssen Biotech Inc |
Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
|
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
SG11201803956UA
(en)
|
2015-12-01 |
2018-06-28 |
Genmab Bv |
Anti-dr5 antibodies and methods of use thereof
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CR20180318A
(es)
|
2015-12-14 |
2018-09-19 |
Macrogenics Inc |
Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
|
|
CN106883297B
(zh)
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
EP3389713A2
(en)
|
2015-12-17 |
2018-10-24 |
Novartis AG |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
JP2019502698A
(ja)
|
2015-12-17 |
2019-01-31 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用
|
|
SG10201707267RA
(en)
|
2015-12-18 |
2017-10-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
SI3390442T1
(sl)
|
2015-12-18 |
2024-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelesa proti c5 in postopki uporabe
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
|
EP3397646A1
(en)
*
|
2015-12-28 |
2018-11-07 |
Massachusetts Institute of Technology |
Bispecific antibodies having constant region mutations and uses therefor
|
|
WO2017115773A1
(ja)
|
2015-12-28 |
2017-07-06 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
EP3400246B1
(en)
|
2016-01-08 |
2020-10-21 |
H. Hoffnabb-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
BR112018014762A2
(pt)
|
2016-01-20 |
2018-12-26 |
Genentech Inc |
método de tratamento da doença de alzheimer (da) precoce
|
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
|
CN109069626A
(zh)
|
2016-02-12 |
2018-12-21 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
|
KR20180119632A
(ko)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US12391759B2
(en)
|
2016-03-02 |
2025-08-19 |
Momenta Pharmaceuticals, Inc. |
Methods related to engineered Fc constructs
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017162587A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CN121431692A
(zh)
|
2016-03-25 |
2026-01-30 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
|
SG11201807279QA
(en)
|
2016-03-31 |
2018-09-27 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
|
WO2017177013A1
(en)
|
2016-04-06 |
2017-10-12 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
EP3442579A4
(en)
|
2016-04-15 |
2019-12-18 |
Immunext Inc. |
ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
|
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
MX395074B
(es)
|
2016-04-15 |
2025-03-24 |
Bioatla Llc |
Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
|
|
CA3021027A1
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
CA3015371A1
(en)
|
2016-04-20 |
2017-10-26 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
SG10202010155YA
(en)
|
2016-04-20 |
2020-11-27 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
UA126900C2
(uk)
|
2016-04-28 |
2023-02-22 |
Чугаі Сейяку Кабусікі Кайся |
Антитіловмісний препарат
|
|
AU2017259869A1
(en)
|
2016-05-02 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
|
CN109071623B
(zh)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
PL3455261T3
(pl)
|
2016-05-13 |
2022-12-12 |
Bioatla, Inc. |
Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
|
|
EP3458608B1
(en)
|
2016-05-17 |
2025-07-23 |
F. Hoffmann-La Roche AG |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック， インコーポレイテッド |
Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
|
|
EP3484514B1
(en)
*
|
2016-05-23 |
2023-12-06 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
|
CN109475627B
(zh)
*
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
MA45255A
(fr)
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
|
MX2018014375A
(es)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y metodos de uso.
|
|
HRP20241323T1
(hr)
|
2016-06-17 |
2024-12-20 |
F. Hoffmann - La Roche Ag |
Pročišćavanje multispecifičnih protutijela
|
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
HRP20240603T1
(hr)
|
2016-07-01 |
2024-07-19 |
Resolve Therapeutics, Llc |
Optimizirane fuzije binukleaze i postupci njihove upotrebe
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
EP3484922A1
(en)
|
2016-07-14 |
2019-05-22 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
LT3496739T
(lt)
|
2016-07-15 |
2021-05-25 |
Acceleron Pharma Inc. |
Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti
|
|
CN110461315B
(zh)
|
2016-07-15 |
2025-05-02 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
|
US20230075499A1
(en)
*
|
2016-07-19 |
2023-03-09 |
Ibentrus, Inc. |
Bispecific proteins and methods for preparing same
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
CA3218290A1
(en)
|
2016-07-22 |
2018-01-25 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
|
SI3490582T1
(sl)
|
2016-07-27 |
2024-09-30 |
Acceleron Pharma Inc. |
Sestavki za uporabo proti zdravljenju mielofibroze
|
|
TW201806619A
(zh)
|
2016-07-28 |
2018-03-01 |
瑞士商諾華公司 |
嵌合抗原受體及pd-1抑制劑之組合療法
|
|
JP7050677B2
(ja)
|
2016-07-29 |
2022-04-08 |
中外製薬株式会社 |
増強されたｆｖｉｉｉ補因子機能代替活性を有する二重特異性抗体
|
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018026942A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Merrimack Pharmaceuticals, Inc. |
Heteromeric polypeptides
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
IL264626B
(en)
|
2016-08-05 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Composition for prophylaxis or treatment of il-8 related diseases
|
|
BR112019002394B1
(pt)
|
2016-08-10 |
2021-12-21 |
Ajou University Industry-Academic Cooperation Foundation |
Proteína heterodimérica fundida com fc e seu uso
|
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック， インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
|
EP3502250B1
(en)
|
2016-08-22 |
2024-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Gene-modified rodent expressing human gpc3 polypeptide
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
ES2958593T3
(es)
|
2016-09-23 |
2024-02-12 |
Hoffmann La Roche |
Usos de antagonistas de IL-13 para el tratamiento de la dermatitis atópica
|
|
CN109790215B
(zh)
|
2016-09-29 |
2023-06-30 |
北京韩美药品有限公司 |
异源二聚体免疫球蛋白构建体和其制备方法
|
|
EP3519820B1
(en)
|
2016-09-30 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
AU2017340504A1
(en)
|
2016-10-05 |
2019-04-11 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
|
WO2018067879A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Alk4:actriib heteromultimers and uses thereof
|
|
US11267865B2
(en)
*
|
2016-10-05 |
2022-03-08 |
Acceleron Pharma Inc. |
Variant ActRIIB proteins and uses thereof
|
|
JP7579056B2
(ja)
|
2016-10-06 |
2024-11-07 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
JP7142630B2
(ja)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
|
|
KR20240000650A
(ko)
|
2016-10-19 |
2024-01-02 |
인벤라 인코포레이티드 |
항체 구조물
|
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
|
WO2018083126A1
(en)
|
2016-11-01 |
2018-05-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
CN110312523B
(zh)
|
2016-11-08 |
2024-04-26 |
齐鲁皮吉特湾生物治疗有限公司 |
抗pd1和抗ctla4抗体
|
|
US11013785B2
(en)
|
2016-11-10 |
2021-05-25 |
Keros Therapeutics, Inc. |
Activin receptor type IIA variants and methods of use thereof
|
|
MA46753A
(fr)
|
2016-11-14 |
2019-09-18 |
Amgen Inc |
Protéines de liaison à l'antigène bispécifiques ou biparatopiques et utilisations de celles-ci
|
|
CA3042435A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
PE20191080A1
(es)
|
2016-11-18 |
2019-08-20 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
PE20200012A1
(es)
|
2016-11-23 |
2020-01-06 |
Bioverativ Therapeutics Inc |
Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x
|
|
KR102645073B1
(ko)
|
2016-12-07 |
2024-03-11 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
|
EP3551220B1
(en)
|
2016-12-07 |
2025-01-29 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
CN110114674B
(zh)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
确定肿瘤样品中存在靶抗原的方法
|
|
CN117752798A
(zh)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
|
EP3559034B1
(en)
|
2016-12-20 |
2020-12-02 |
H. Hoffnabb-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
CN110088291A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
|
AU2017381657B2
(en)
|
2016-12-21 |
2020-07-23 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
|
KR102390246B1
(ko)
|
2016-12-21 |
2022-04-22 |
에프. 호프만-라 로슈 아게 |
항체의 시험관내 글리코조작에 있어서의 효소의 재사용
|
|
JP7215999B2
(ja)
|
2016-12-21 |
2023-01-31 |
エフ．ホフマン－ラ ロシュ アーゲー |
抗体またはリガンドの結合および機能を決定するためのアッセイ法
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
MA47200A
(fr)
|
2017-01-03 |
2019-11-13 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
|
|
CN117886928A
(zh)
|
2017-01-06 |
2024-04-16 |
动量制药公司 |
与经工程改造的Fc构建体相关的组合物和方法
|
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110234355B
(zh)
|
2017-02-01 |
2021-11-09 |
浙江时迈药业有限公司 |
单体人IgG1 Fc和双特异性抗体
|
|
WO2018147245A1
(ja)
|
2017-02-07 |
2018-08-16 |
第一三共株式会社 |
抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
|
|
KR20190118172A
(ko)
|
2017-02-08 |
2019-10-17 |
드래곤플라이 쎄라퓨틱스, 인크. |
천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
|
|
EP3579876A4
(en)
*
|
2017-02-10 |
2020-11-18 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BIND BCMA, NKG2D AND CD16
|
|
US10738131B2
(en)
|
2017-02-10 |
2020-08-11 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
CN110945021B
(zh)
|
2017-02-10 |
2025-09-12 |
根马布私人有限公司 |
多肽变体及其用途
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
JP7685821B2
(ja)
|
2017-02-20 |
2025-05-30 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
|
|
EP3586872A4
(en)
|
2017-02-24 |
2020-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
PHARMACEUTICAL COMPOSITION, ANTIGEN BINDING MOLECULES, METHOD OF TREATMENT AND METHOD OF SCREENING
|
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
US11685776B2
(en)
|
2017-03-02 |
2023-06-27 |
Novartis Ag |
Engineered heterodimeric proteins
|
|
IL322509A
(en)
|
2017-03-09 |
2025-10-01 |
Genmab As |
Antibodies against PD-L1
|
|
PE20191360A1
(es)
|
2017-03-10 |
2019-10-01 |
Hoffmann La Roche |
Metodo para producir anticuerpos multiespecificos
|
|
MA49279A
(fr)
|
2017-03-22 |
2020-02-05 |
Hoffmann La Roche |
Compositions d'anticorps optimisées pour le traitement de troubles oculaires
|
|
KR102715397B1
(ko)
|
2017-03-22 |
2024-10-10 |
아센디스 파마 에이에스 |
히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
US20200270359A1
(en)
|
2017-03-31 |
2020-08-27 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
KR20260006707A
(ko)
|
2017-03-31 |
2026-01-13 |
메뤼스 엔.페. |
NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB2 및 ErbB3 결합 이중특이적 항체
|
|
KR102629905B1
(ko)
|
2017-04-01 |
2024-01-30 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
|
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
WO2018184964A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
WO2018184966A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding to steap-1
|
|
EP3606956B1
(en)
|
2017-04-04 |
2024-07-31 |
F. Hoffmann-La Roche AG |
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
|
|
EP3606955B1
(en)
|
2017-04-05 |
2024-11-06 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
EP4112644A1
(en)
|
2017-04-05 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Anti-lag3 antibodies
|
|
TW202515920A
(zh)
|
2017-04-11 |
2025-04-16 |
美商因荷布瑞克斯生物科學公司 |
具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
|
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
|
US20190078160A1
(en)
|
2017-04-21 |
2019-03-14 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
SG10201913582XA
(en)
|
2017-04-26 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
AU2018271157C1
(en)
|
2017-05-17 |
2021-11-18 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3630829A1
(en)
|
2017-06-02 |
2020-04-08 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
JP2020522543A
(ja)
|
2017-06-07 |
2020-07-30 |
ゲンマブ ビー．ブイ． |
変異ＩｇＧ六量体に基づく治療用抗体
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
US11312783B2
(en)
|
2017-06-22 |
2022-04-26 |
Novartis Ag |
Antibody molecules to CD73 and uses thereof
|
|
KR20200022447A
(ko)
|
2017-06-27 |
2020-03-03 |
노파르티스 아게 |
항-tim-3 항체의 투여 요법 및 그의 용도
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
CA3069469A1
(en)
|
2017-07-21 |
2019-01-24 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
KR102670957B1
(ko)
|
2017-07-26 |
2024-05-31 |
포티 세븐, 인코포레이티드 |
항-sirp-알파 항체 및 관련 방법
|
|
CA3071211A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
DK3665198T3
(da)
|
2017-08-09 |
2025-04-28 |
Merus Nv |
Antistoffer, der binder egfr og cmet
|
|
AU2018316343B2
(en)
|
2017-08-11 |
2025-06-12 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
EP3672986A1
(en)
|
2017-08-22 |
2020-07-01 |
Sanabio, LLC |
Soluble interferon receptors and uses thereof
|
|
IL273592B2
(en)
|
2017-09-29 |
2025-11-01 |
Chugai Pharmaceutical Co Ltd |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
MX2020003497A
(es)
|
2017-10-20 |
2020-07-22 |
Hoffmann La Roche |
Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
KR102831164B1
(ko)
|
2017-10-30 |
2025-07-07 |
에프. 호프만-라 로슈 아게 |
단일특이적 항체로부터 다중특이적 항체의 생체내 생성 방법
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
MA50505A
(fr)
|
2017-11-01 |
2020-09-09 |
Hoffmann La Roche |
Anticorps 2 + 1 bispécifiques (contorsbodies)
|
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
|
CA3079129C
(en)
|
2017-11-01 |
2023-02-28 |
F. Hoffmann-La Roche Ag |
Trifab-contorsbody
|
|
JPWO2019088143A1
(ja)
|
2017-11-01 |
2020-11-12 |
中外製薬株式会社 |
生物活性が低下した抗体バリアントおよびアイソフォーム
|
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
|
MX2020004573A
(es)
|
2017-11-01 |
2020-09-25 |
Hoffmann La Roche |
Terapia de combinacion con agonistas de ox40 dirigidos.
|
|
ES2984919T3
(es)
|
2017-11-06 |
2024-10-31 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
EP4428147A3
(en)
|
2017-11-09 |
2024-10-30 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
CN111556895B
(zh)
|
2017-11-14 |
2024-09-13 |
中外制药株式会社 |
抗-c1s抗体及使用方法
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
CN111527107B
(zh)
|
2017-12-21 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
结合hla-a2/wt1的抗体
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
EP3728327A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
AU2018396964C1
(en)
|
2017-12-28 |
2024-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against PD-L1
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2019129677A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Anti-vegf antibodies and methods of use
|
|
MX2020007077A
(es)
|
2018-01-04 |
2020-10-28 |
Iconic Therapeutics Inc |
Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
WO2019140320A1
(en)
|
2018-01-12 |
2019-07-18 |
Genzyme Corporation |
Methods for the quantitation of polypeptides
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US11472874B2
(en)
|
2018-01-31 |
2022-10-18 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
安定化された免疫グロブリンドメイン
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
CN119733046A
(zh)
|
2018-02-06 |
2025-04-01 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
DK3749346T3
(da)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
Antistof variable domænekombinationer rettet mod nkg2d-receptoren
|
|
CN112040971A
(zh)
|
2018-02-08 |
2020-12-04 |
蜻蜓疗法股份有限公司 |
涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
JP7418337B2
(ja)
|
2018-02-09 |
2024-01-19 |
ジェネンテック， インコーポレイテッド |
マスト細胞媒介性炎症性疾患の治療法及び診断法
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP2021512624A
(ja)
|
2018-02-11 |
2021-05-20 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
|
|
WO2019160007A1
(ja)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
TW201942134A
(zh)
|
2018-02-20 |
2019-11-01 |
美商蜻蜓醫療公司 |
結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
|
|
WO2019175198A2
(en)
|
2018-03-12 |
2019-09-19 |
Genmab A/S |
Antibodies
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
AU2019236372B2
(en)
|
2018-03-13 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
|
EP3775184B1
(en)
|
2018-03-29 |
2025-12-10 |
F. Hoffmann-La Roche AG |
Modulating lactogenic activity in mammalian cells
|
|
EP3774917B1
(en)
|
2018-03-30 |
2025-10-29 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
|
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
KR20200140878A
(ko)
|
2018-04-09 |
2020-12-16 |
암젠 인크 |
성장 분화 인자 15 융합 단백질
|
|
CA3096123A1
(en)
|
2018-04-11 |
2019-10-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
SG11202007961QA
(en)
|
2018-04-13 |
2020-09-29 |
Hoffmann La Roche |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
MA52485A
(fr)
|
2018-05-03 |
2021-03-10 |
Genmab Bv |
Combinaisons de variants d'anticorps et utilisations associées
|
|
CN112166196A
(zh)
|
2018-05-18 |
2021-01-01 |
豪夫迈·罗氏有限公司 |
大核酸的靶向细胞内递送
|
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
MX2020011828A
(es)
|
2018-05-25 |
2021-02-09 |
Alector Llc |
Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11492409B2
(en)
|
2018-06-01 |
2022-11-08 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
CN112469440B
(zh)
|
2018-06-18 |
2024-09-06 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
|
PE20210418A1
(es)
|
2018-06-19 |
2021-03-08 |
Atarga Llc |
Moleculas de anticuerpo de componente de complemento 5 y sus usos
|
|
JP7513530B2
(ja)
|
2018-06-22 |
2024-07-09 |
ジェンマブ ホールディング ビー．ブイ． |
抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
|
|
CN112384532B
(zh)
|
2018-06-29 |
2025-01-10 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
WO2020007817A1
(en)
|
2018-07-04 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020012038A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
MX2019012869A
(es)
|
2018-07-13 |
2020-01-23 |
Alector Llc |
Anticuerpos anti-sortilina y metodos para su uso.
|
|
MA53122A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Variants d'anticorps cd38 et leurs utilisations
|
|
US11214619B2
(en)
|
2018-07-20 |
2022-01-04 |
Surface Oncology, Inc. |
Anti-CD112R compositions and methods
|
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
MX2021000827A
(es)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
|
|
AU2019318083A1
(en)
|
2018-08-08 |
2021-02-25 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
|
|
KR20250112921A
(ko)
|
2018-08-08 |
2025-07-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MA50586A
(fr)
|
2018-08-09 |
2020-09-16 |
Regeneron Pharma |
Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
JP7523349B2
(ja)
|
2018-08-29 |
2024-07-26 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
JP7482853B2
(ja)
|
2018-09-10 |
2024-05-14 |
ジェネンテック， インコーポレイテッド |
アフィニティキャピラリ電気泳動のシステム及び方法
|
|
US11573226B2
(en)
|
2018-09-10 |
2023-02-07 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
TWI841595B
(zh)
|
2018-09-10 |
2024-05-11 |
大陸商南京傳奇生物科技有限公司 |
針對ｃｄ３３之單域抗體及其構築體
|
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
EP3856778A1
(en)
|
2018-09-24 |
2021-08-04 |
The Medical College of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
|
MX2021003548A
(es)
|
2018-10-01 |
2021-05-27 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
|
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
JP2022512684A
(ja)
|
2018-10-11 |
2022-02-07 |
インヒブルクス インコーポレイテッド |
Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CN113518647A
(zh)
|
2018-10-11 |
2021-10-19 |
印希比股份有限公司 |
5t4单域抗体及其治疗性组合物
|
|
EP3864049A1
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
US11377477B2
(en)
|
2018-10-12 |
2022-07-05 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
EP3870598A1
(en)
|
2018-10-23 |
2021-09-01 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
MX2021004774A
(es)
|
2018-10-29 |
2021-08-24 |
Hoffmann La Roche |
Formulacion de anticuerpos.
|
|
CN113454111A
(zh)
|
2018-11-06 |
2021-09-28 |
健玛保 |
抗体配制剂
|
|
BR112021008795A2
(pt)
|
2018-11-13 |
2021-08-31 |
Compass Therapeutics Llc |
Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
CA3121699A1
(en)
|
2018-12-05 |
2020-06-11 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
CA3119798A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック， インコーポレイテッド |
Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
|
AU2019402097A1
(en)
|
2018-12-17 |
2021-06-10 |
Revitope Limited |
Twin immune cell engager
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
EP3897637A1
(en)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3897647B1
(en)
|
2018-12-20 |
2023-11-01 |
Novartis AG |
Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
AR117453A1
(es)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
Fc de anticuerpos modificados y métodos para utilizarlas
|
|
CN113621062B
(zh)
|
2018-12-21 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
EP3898683A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
EP3898673A1
(en)
|
2018-12-21 |
2021-10-27 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
|
US11608376B2
(en)
|
2018-12-21 |
2023-03-21 |
Hoffmann-La Roche Inc. |
Tumor-targeted agonistic CD28 antigen binding molecules
|
|
JP2022515424A
(ja)
|
2018-12-24 |
2022-02-18 |
サノフイ |
突然変異ｆａｂドメインを有する多重特異性結合タンパク質
|
|
CA3124770A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
EP3903102B1
(en)
|
2018-12-30 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Ph-gradient spr-based binding assay
|
|
KR20210113261A
(ko)
|
2019-01-04 |
2021-09-15 |
리졸브 테라퓨틱스, 엘엘씨 |
뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
|
|
PH12021551475A1
(en)
*
|
2019-01-07 |
2022-05-02 |
Shattuck Labs Inc |
Heterodimeric proteins for modulating gamma delta t cells
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
JP7303314B2
(ja)
|
2019-01-18 |
2023-07-04 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
|
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
CN114026122B
(zh)
|
2019-02-21 |
2024-12-31 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
CN114127113A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与钙网蛋白结合的多功能分子及其用途
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
|
CA3130628A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
PH12021552030A1
(en)
|
2019-02-26 |
2022-08-15 |
Janssen Biotech Inc |
Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
|
|
BR112021016955A2
(pt)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
|
|
WO2020180811A1
(en)
|
2019-03-04 |
2020-09-10 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
KR20250143873A
(ko)
|
2019-03-08 |
2025-10-02 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
|
EP3938403A1
(en)
|
2019-03-14 |
2022-01-19 |
F. Hoffmann-La Roche AG |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
WO2020200941A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Spr-based binding assay for the functional analysis of multivalent molecules
|
|
CN113677701B
(zh)
|
2019-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
产生亲合结合多特异性抗体的方法
|
|
EP3946593A1
(en)
|
2019-03-29 |
2022-02-09 |
Atarga, LLC |
Anti fgf23 antibody
|
|
CN113677403B
(zh)
|
2019-04-12 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
MX2021012871A
(es)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
|
|
MX2021012931A
(es)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Polipeptidos multiespecificos activables y terapeuticos con semivida extendida.
|
|
BR112021020859A2
(pt)
|
2019-04-25 |
2022-01-04 |
Hoffmann La Roche |
Conjuntos de polipeptídeos, método para gerar um polipeptídeo, polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico e segundo polipeptídeo precursor heterodimérico
|
|
MX2021013220A
(es)
|
2019-05-03 |
2021-12-10 |
Genentech Inc |
Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.
|
|
EP3966244A1
(en)
|
2019-05-09 |
2022-03-16 |
F. Hoffmann-La Roche AG |
Methods of making antibodies
|
|
WO2020225456A1
(en)
|
2019-05-09 |
2020-11-12 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
EP3969907B1
(en)
|
2019-05-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
|
TW202108178A
(zh)
|
2019-05-14 |
2021-03-01 |
美商建南德克公司 |
使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
|
|
KR20250156861A
(ko)
|
2019-05-21 |
2025-11-03 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
CN114173810B
(zh)
|
2019-05-21 |
2024-09-06 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
AU2020282791A1
(en)
|
2019-05-31 |
2021-12-09 |
ALX Oncology Inc. |
Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
|
|
MX2021015007A
(es)
|
2019-06-10 |
2022-01-31 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de citocinas.
|
|
AU2020291527A1
(en)
|
2019-06-11 |
2022-01-20 |
Alector Llc |
Anti-Sortilin antibodies for use in therapy
|
|
CN118547004A
(zh)
|
2019-06-19 |
2024-08-27 |
豪夫迈·罗氏有限公司 |
通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
|
|
CA3140192A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
MX2021015540A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
|
KR20220010019A
(ko)
|
2019-06-19 |
2022-01-25 |
에프. 호프만-라 로슈 아게 |
정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 2가 이중특이성 항체 발현 세포를 생성하는 방법
|
|
BR112021025500A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Métodos para produzir um anticorpo multivalente biespecífico e para produzir uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição
|
|
CN117821393A
(zh)
|
2019-06-26 |
2024-04-05 |
豪夫迈·罗氏有限公司 |
具有sirt-1基因敲除的哺乳动物细胞系
|
|
KR20220025848A
(ko)
|
2019-06-26 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
Cea 및 4-1bbl에 결합하는 항체의 융합
|
|
CN114531878A
(zh)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
|
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AU2020309958A1
(en)
|
2019-07-10 |
2021-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
CN115175932B
(zh)
|
2019-07-16 |
2025-10-31 |
赛诺菲 |
用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
|
|
CR20220078A
(es)
|
2019-07-31 |
2022-06-24 |
Alector Llc |
Anticuerpos anti-ms4a4a y métodos de uso de los mismos
|
|
JP2022543553A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
TWI780464B
(zh)
|
2019-08-06 |
2022-10-11 |
香港商新旭生技股份有限公司 |
結合至病理性ｔａｕ種類之抗體及其用途
|
|
WO2021026409A1
(en)
|
2019-08-08 |
2021-02-11 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
TW202120534A
(zh)
|
2019-08-13 |
2021-06-01 |
美商安進公司 |
用於擴增調節性ｔ細胞之介白素－２突變蛋白
|
|
JP7792330B2
(ja)
|
2019-09-03 |
2025-12-25 |
アムジエン・インコーポレーテツド |
Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法
|
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
TW202126698A
(zh)
|
2019-09-18 |
2021-07-16 |
美商建南德克公司 |
抗ｋｌｋ７抗體、抗ｋｌｋ５抗體、多重特異性抗ｋｌｋ５／ｋｌｋ７抗體、及使用方法
|
|
JP2022549218A
(ja)
|
2019-09-20 |
2022-11-24 |
ジェネンテック， インコーポレイテッド |
抗トリプターゼ抗体の投薬
|
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing GenScript Biotech Co., Ltd. |
ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CN118557750A
(zh)
|
2019-10-18 |
2024-08-30 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
|
IL292347A
(en)
|
2019-10-21 |
2022-06-01 |
Novartis Ag |
Combination treatments with ventoclax and tim-3 inhibitors
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
|
EP4058593A4
(en)
|
2019-11-12 |
2023-11-15 |
Foundation Medicine, Inc. |
METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
|
|
WO2021094508A1
(en)
|
2019-11-15 |
2021-05-20 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in aqueous protein solutions
|
|
EP4061837A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
|
|
CA3160438A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
BR112022008817A2
(pt)
|
2019-11-27 |
2022-07-26 |
Alx Oncology Inc |
Terapias combinadas para tratamento de câncer
|
|
CN113135996A
(zh)
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
EP4072584B1
(en)
|
2019-12-13 |
2026-01-28 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
PE20221506A1
(es)
|
2019-12-17 |
2022-10-04 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia
|
|
MX2022006578A
(es)
|
2019-12-17 |
2022-07-04 |
Pfizer |
Anticuerpos especificos para cd47, pd-l1 y sus usos.
|
|
US11739142B2
(en)
|
2019-12-18 |
2023-08-29 |
Hoffmann-La Roche Inc. |
Bispecific anti-CCL2 antibodies
|
|
CR20220256A
(es)
|
2019-12-18 |
2022-08-31 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
|
IL293889A
(en)
|
2019-12-20 |
2022-08-01 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
CN114846024A
(zh)
|
2019-12-20 |
2022-08-02 |
豪夫迈·罗氏有限公司 |
Il-37融合蛋白及其用途
|
|
US12091440B2
(en)
|
2019-12-20 |
2024-09-17 |
Regeneron Pharmaceuticals, Inc. |
IL2 and peptide-MHC complex fusion proteins and methods of use thereof
|
|
WO2021133723A2
(en)
|
2019-12-23 |
2021-07-01 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
|
MY202559A
(en)
|
2019-12-27 |
2024-05-08 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibody and use thereof
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
CN114929734A
(zh)
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
新型含有4-1bbl三聚体的抗原结合分子
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
KR20220129003A
(ko)
|
2020-01-15 |
2022-09-22 |
에프. 호프만-라 로슈 아게 |
재조합 단백질 제조 공정으로부터 불순물을 감소시키기 위한 방법
|
|
BR112022013553A2
(pt)
|
2020-01-16 |
2022-09-06 |
Genmab As |
Composição farmacêutica, anticorpo, e, método para tratar uma doença
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
WO2021144657A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
WO2021160154A1
(zh)
|
2020-02-10 |
2021-08-19 |
上海诗健生物科技有限公司 |
Cldn18.2抗体及其用途
|
|
KR20220140786A
(ko)
|
2020-02-10 |
2022-10-18 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
클라우딘18.2 항체 및 그것의 사용
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
MX2022010549A
(es)
|
2020-02-26 |
2022-11-16 |
Biograph 55 Inc |
Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.
|
|
MX2022010685A
(es)
|
2020-02-27 |
2022-09-23 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
|
|
PE20230252A1
(es)
|
2020-03-13 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos de estos
|
|
AU2021236906A1
(en)
|
2020-03-18 |
2022-08-18 |
Genmab A/S |
Antibodies binding to B7H4
|
|
KR20250074688A
(ko)
|
2020-03-19 |
2025-05-27 |
제넨테크, 인크. |
동종형 선택적 항-tgf-베타 항체 및 이용 방법
|
|
MX2022011752A
(es)
|
2020-03-24 |
2022-10-18 |
Genentech Inc |
Agentes de fijacion a tie2 y metodos de uso.
|
|
CA3173162A1
(en)
|
2020-03-25 |
2021-09-30 |
Eli Lilly And Company |
Multispecific binding proteins and methods of developing the same
|
|
US12098365B2
(en)
|
2020-03-26 |
2024-09-24 |
Genentech, Inc. |
Modified mammalian cells
|
|
EP4126241A1
(en)
|
2020-03-27 |
2023-02-08 |
Novartis AG |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
KR20220160598A
(ko)
|
2020-03-30 |
2022-12-06 |
고쿠리츠다이가쿠호진 미에다이가쿠 |
이중 특이적 항체
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
WO2021201202A1
(ja)
|
2020-04-02 |
2021-10-07 |
中外製薬株式会社 |
多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
|
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
がんに対する治療方法及び診断方法
|
|
MX2022012541A
(es)
|
2020-04-15 |
2022-11-07 |
Hoffmann La Roche |
Inmunoconjugados.
|
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
CR20220531A
(es)
|
2020-04-24 |
2022-11-28 |
Hoffmann La Roche |
Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
|
|
AU2021259861A1
(en)
|
2020-04-24 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-CD79b immunoconjugates
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
US20230172923A1
(en)
|
2020-04-30 |
2023-06-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
|
WO2021225892A1
(en)
|
2020-05-03 |
2021-11-11 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
|
EP4146271A4
(en)
|
2020-05-06 |
2024-09-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
|
|
US12435154B2
(en)
|
2020-05-08 |
2025-10-07 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
|
CN115551540A
(zh)
|
2020-05-11 |
2022-12-30 |
豪夫迈·罗氏有限公司 |
使用经修饰的pbmc和免疫缀合物的组合疗法
|
|
IL298007A
(en)
|
2020-05-12 |
2023-01-01 |
Regeneron Pharma |
Novel il10 agonists and methods of use thereof
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
CN115605184A
(zh)
|
2020-05-15 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
防止胃肠外蛋白质溶液中的可见颗粒形成
|
|
US20230192797A1
(en)
|
2020-05-18 |
2023-06-22 |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
Human il-15 mutant and uses thereof
|
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
|
KR20230012559A
(ko)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
|
EP4157461A1
(en)
|
2020-05-29 |
2023-04-05 |
23Andme, Inc. |
Anti-cd200r1 antibodies and methods of use thereof
|
|
MX2022015206A
(es)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso.
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
IL298402A
(en)
|
2020-06-19 |
2023-01-01 |
Hoffmann La Roche |
Antibodies that bind to CD3 and CD19
|
|
AR122657A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
CA3185513A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
|
PH12022500027A1
(en)
|
2020-06-19 |
2024-03-25 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
AU2021291002A1
(en)
|
2020-06-19 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Protease-activated T cell bispecific antibodies
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
AU2021292932A1
(en)
|
2020-06-19 |
2023-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-T cell antigen-binding molecule for use in combination with angiogenesis inhibitor
|
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗ｉｌ－３６抗体およびその使用方法
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP7678005B2
(ja)
|
2020-06-23 |
2025-05-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２を標的とするアゴニストＣＤ２８抗原結合分子
|
|
MX2022016453A
(es)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Lineas celulares resistentes a la apoptosis.
|
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CN116133689A
(zh)
|
2020-07-07 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
|
|
KR20230037578A
(ko)
|
2020-07-10 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
암 세포에 결합하고 방사성 핵종을 상기 세포로 표적화하는 항체
|
|
MX2023000547A
(es)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
|
|
US20230303682A1
(en)
|
2020-07-17 |
2023-09-28 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Methods of Use
|
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
BR112023001143A2
(pt)
|
2020-07-21 |
2023-02-14 |
Genentech Inc |
Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
|
|
US20230293680A1
(en)
|
2020-07-23 |
2023-09-21 |
Genmab B.V. |
A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
KR20230048059A
(ko)
|
2020-07-31 |
2023-04-10 |
추가이 세이야쿠 가부시키가이샤 |
키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN116194477A
(zh)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
冠状病毒s蛋白的结合剂
|
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
CA3190766A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN116249718A
(zh)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
结合至钙网蛋白的多功能性分子及其用途
|
|
WO2022047046A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
|
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230310599A1
(en)
|
2020-09-02 |
2023-10-05 |
Genmab A/S |
Antibody therapy
|
|
BR112023004296A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma de célula b grande difusa em um indivíduo humano
|
|
CN116437956A
(zh)
|
2020-09-10 |
2023-07-14 |
健玛保 |
用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
AU2021342343A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
AU2021341526A1
(en)
|
2020-09-14 |
2023-04-27 |
IGI Therapeutics SA |
Antibodies that bind to il1rap and uses thereof
|
|
JP2023542079A
(ja)
|
2020-09-21 |
2023-10-05 |
ジェネンテック， インコーポレイテッド |
多重特異性抗体の精製
|
|
CN116391037A
(zh)
|
2020-09-24 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
具有基因敲除的哺乳动物细胞系
|
|
CA3193914A1
(en)
|
2020-10-02 |
2022-04-07 |
Louise KOOPMAN |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
|
WO2022072882A1
(en)
|
2020-10-02 |
2022-04-07 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US11926667B2
(en)
|
2020-10-13 |
2024-03-12 |
Janssen Biotech, Inc. |
Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
|
|
KR20230091871A
(ko)
|
2020-10-20 |
2023-06-23 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
|
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
|
AR123862A1
(es)
|
2020-10-21 |
2023-01-18 |
Boehringer Ingelheim Int |
Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
|
|
EP4237003A4
(en)
|
2020-10-28 |
2025-07-09 |
Janssen Biotech Inc |
COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
|
|
EP4237451A1
(en)
|
2020-11-02 |
2023-09-06 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
KR20230107305A
(ko)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
|
JP2023549504A
(ja)
|
2020-11-13 |
2023-11-27 |
ノバルティス アーゲー |
キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法
|
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
|
WO2022101088A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
|
CN116723861A
(zh)
|
2020-12-02 |
2023-09-08 |
上海复宏汉霖生物技术股份有限公司 |
抗GARP/TGFβ抗体及使用方法
|
|
KR20230117169A
(ko)
|
2020-12-02 |
2023-08-07 |
알렉터 엘엘씨 |
항-소르틸린 항체의 사용 방법
|
|
CA3197740A1
(en)
|
2020-12-04 |
2022-06-09 |
F. Hoffman-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
AU2021398385A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
|
WO2022129313A1
(en)
|
2020-12-18 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Precursor proteins and kit for targeted therapy
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
MX2023007846A
(es)
|
2021-01-06 |
2023-07-07 |
Hoffmann La Roche |
Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
US20240082437A1
(en)
|
2021-01-12 |
2024-03-14 |
Hoffmann-La Roche Inc. |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
US20240173442A1
(en)
|
2021-01-13 |
2024-05-30 |
Hoffmann-La Roche Inc. |
Combination therapy
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック， インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
US11639396B2
(en)
|
2021-02-16 |
2023-05-02 |
Janssen Biotech, Inc. |
Antibody binding to a linker peptide
|
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
|
JP7773237B2
(ja)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Ｃｄ４７に対する単一ドメイン抗体及びその用途
|
|
BR112023016706A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
CN117440832A
(zh)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
包括抗bcma抗体的抗体-药物缀合物
|
|
CN117222663A
(zh)
|
2021-03-03 |
2023-12-12 |
蜻蜓疗法股份有限公司 |
使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
|
|
AU2022231874A1
(en)
|
2021-03-09 |
2023-07-27 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
EP4304732A1
(en)
|
2021-03-12 |
2024-01-17 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
CN116964085A
(zh)
|
2021-03-12 |
2023-10-27 |
根马布股份公司 |
非激活抗体变体
|
|
KR20230156373A
(ko)
|
2021-03-15 |
2023-11-14 |
제넨테크, 인크. |
루푸스 신염의 치료 조성물 및 치료 방법
|
|
CN116981696A
(zh)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
US20240166738A1
(en)
|
2021-03-23 |
2024-05-23 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
JP2024512035A
(ja)
|
2021-03-24 |
2024-03-18 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃｄ２２及びｃｄ７９ｂを標的とする抗体
|
|
AU2022246275A1
(en)
|
2021-03-26 |
2023-11-09 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
|
IL305847A
(en)
|
2021-03-26 |
2023-11-01 |
Innate Pharma |
Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
|
|
PH12023500022A1
(en)
|
2021-03-29 |
2024-03-11 |
Daiichi Sankyo Co Ltd |
Stable multispecific molecule and use thereof
|
|
WO2022206872A1
(zh)
|
2021-03-31 |
2022-10-06 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022214565A1
(en)
|
2021-04-09 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
AU2022253902A1
(en)
|
2021-04-10 |
2023-11-02 |
Genmab A/S |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
|
JP7742892B2
(ja)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
WO2022233764A1
(en)
|
2021-05-03 |
2022-11-10 |
UCB Biopharma SRL |
Antibodies
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
BR112023022878A2
(pt)
|
2021-05-04 |
2024-01-23 |
Regeneron Pharma |
Agonistas do receptor fgf21 multiespecíficos e seus usos
|
|
BR112023021089A2
(pt)
|
2021-05-07 |
2023-12-12 |
Genmab As |
Composição farmacêutica, método para tratar uma doença, método para tratar câncer em um indivíduo, uso da composição farmacêutica, forma de dosagem unitária, kit de partes, e, método para preparar uma composição farmacêutica
|
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
|
TW202310876A
(zh)
|
2021-05-12 |
2023-03-16 |
美商建南德克公司 |
使用抗ｃｄ７９ｂ免疫結合物治療瀰漫性大ｂ細胞淋巴瘤之方法
|
|
CA3218542A1
(en)
|
2021-05-12 |
2022-11-17 |
Hua Ying |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
|
CA3216908A1
(en)
|
2021-05-13 |
2022-11-17 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
AR125855A1
(es)
|
2021-05-14 |
2023-08-16 |
Genentech Inc |
Agonistas de trem2
|
|
WO2022237882A1
(zh)
|
2021-05-14 |
2022-11-17 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
JP2024521408A
(ja)
|
2021-06-09 |
2024-05-31 |
イナート・ファルマ・ソシエテ・アノニム |
Ｃｄ２０、ｎｋｐ４６、ｃｄ１６に結合し、かつｉｌ－２にコンジュゲートされた多特異性抗体
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
MX2023014563A
(es)
|
2021-06-09 |
2024-02-08 |
Hoffmann La Roche |
Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
|
|
MX2023014647A
(es)
|
2021-06-09 |
2024-01-31 |
Innate Pharma |
Proteinas de union a nkp46 multiespecificas.
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
AU2022295067A1
(en)
|
2021-06-18 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
WO2022268740A1
(en)
|
2021-06-21 |
2022-12-29 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
US20240294626A1
(en)
|
2021-06-22 |
2024-09-05 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
|
WO2022272128A1
(en)
|
2021-06-24 |
2022-12-29 |
Erasca, Inc. |
Antibodies against egfr and their uses
|
|
AU2022297107B2
(en)
|
2021-06-25 |
2024-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
|
CR20240026A
(es)
|
2021-06-25 |
2024-03-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
US20240343811A1
(en)
|
2021-06-29 |
2024-10-17 |
Shandong Simcere Biopharmacutical Co., Ltd. |
Cd16 antibody and use thereof
|
|
TW202309078A
(zh)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
|
JP2024529339A
(ja)
|
2021-07-13 |
2024-08-06 |
ジェネンテック， インコーポレイテッド |
サイトカイン放出症候群を予測する多変量モデル
|
|
CR20240074A
(es)
|
2021-07-14 |
2024-03-08 |
Genentech Inc |
Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y métodos de uso
|
|
MX2024000501A
(es)
|
2021-07-14 |
2024-01-31 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
|
|
EP4373851A2
(en)
|
2021-07-19 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
JP2024526880A
(ja)
|
2021-07-22 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
脳標的化組成物及びその使用方法
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
|
EP4377347A1
(en)
|
2021-07-27 |
2024-06-05 |
MorphoSys AG |
Combinations of antigen binding molecules
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
JP2024528217A
(ja)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗体および使用方法
|
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
|
JP2024534787A
(ja)
|
2021-08-16 |
2024-09-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
新規なｉｌ２７受容体アゴニスト及びその使用方法
|
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
WO2023028591A1
(en)
|
2021-08-27 |
2023-03-02 |
Genentech, Inc. |
Methods of treating tau pathologies
|
|
JP2024534853A
(ja)
|
2021-08-30 |
2024-09-26 |
ジェネンテック， インコーポレイテッド |
抗ポリビキチン多重特異性抗体
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
AU2022338208A1
(en)
|
2021-09-06 |
2024-03-21 |
Genmab A/S |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20240270874A1
(en)
|
2021-09-23 |
2024-08-15 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-klb antibodies and uses
|
|
CN118562019A
(zh)
*
|
2021-09-30 |
2024-08-30 |
宁波三生生物科技股份有限公司 |
重组促卵泡激素融合蛋白
|
|
CN117916273A
(zh)
|
2021-09-30 |
2024-04-19 |
江苏恒瑞医药股份有限公司 |
抗il23抗体融合蛋白及用途
|
|
JPWO2023058723A1
(sl)
|
2021-10-08 |
2023-04-13 |
|
|
|
CN118414353A
(zh)
|
2021-10-08 |
2024-07-30 |
根马布股份公司 |
与cd30和cd3结合的抗体
|
|
CN118215674A
(zh)
|
2021-10-14 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
新颖白细胞介素-7免疫缀合物
|
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
TW202323281A
(zh)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
|
CA3234162A1
(en)
|
2021-10-15 |
2023-04-20 |
Michele Fiscella |
Antibodies and methods of using thereof
|
|
JP2024539139A
(ja)
|
2021-10-20 |
2024-10-28 |
シンセカイン インコーポレイテッド |
ヘテロ二量体ｆｃサイトカインおよびその使用
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
CN118119642A
(zh)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
工程化Fc变体
|
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
EP4430079A1
(en)
|
2021-11-11 |
2024-09-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4437344A1
(en)
|
2021-11-25 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Quantification of low amounts of antibody sideproducts
|
|
CN118284625A
(zh)
|
2021-11-26 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
|
|
JPWO2023100829A1
(sl)
|
2021-11-30 |
2023-06-08 |
|
|
|
EP4442274A4
(en)
|
2021-12-01 |
2025-12-24 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PREPARING A FORMULATION CONTAINING AN ANTIBODY
|
|
JP2024541668A
(ja)
|
2021-12-03 |
2024-11-08 |
山▲東▼先声生物制▲薬▼有限公司 |
抗ｂｃｍａナノ抗体及びその応用
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
JP2024547020A
(ja)
|
2021-12-17 |
2024-12-26 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体、多重特異性抗体及びその使用方法
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
CN118401674A
(zh)
|
2021-12-21 |
2024-07-26 |
豪夫迈·罗氏有限公司 |
用于确定水解活性的方法
|
|
JP2025500952A
(ja)
|
2021-12-23 |
2025-01-15 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗ｄｌｌ３抗体、その抗体－薬物複合体及びその医薬的使用
|
|
US20250145705A1
(en)
|
2021-12-31 |
2025-05-08 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Gprc5d antibody and application thereof
|
|
WO2023135198A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
EP4469083A1
(en)
|
2022-01-28 |
2024-12-04 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
KR20240135663A
(ko)
|
2022-01-28 |
2024-09-11 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
|
JP2025505611A
(ja)
|
2022-02-07 |
2025-02-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Ｐｓｍａとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
|
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
EP4477674A1
(en)
|
2022-02-09 |
2024-12-18 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
US20240117030A1
(en)
|
2022-03-03 |
2024-04-11 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
|
US20250205350A1
(en)
|
2022-03-10 |
2025-06-26 |
Vivasor, Inc. |
Antibody-Drug Conjugates and Uses Thereof
|
|
CN119173530A
(zh)
|
2022-03-11 |
2024-12-20 |
詹森药业有限公司 |
多特异性抗体及其用途
|
|
KR20240156640A
(ko)
|
2022-03-11 |
2024-10-30 |
얀센 파마슈티카 엔브이 |
다중특이적 항체 및 이의 용도
|
|
CA3254098A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
MX2024011128A
(es)
|
2022-03-14 |
2024-09-18 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
KR20240161968A
(ko)
|
2022-03-16 |
2024-11-13 |
다이이찌 산쿄 가부시키가이샤 |
다중 특이적 분자와 면역 체크 포인트 저해제의 조합
|
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
CN118974096A
(zh)
|
2022-03-25 |
2024-11-15 |
上海复宏汉霖生物技术股份有限公司 |
抗msln抗体及使用方法
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
IL315770A
(en)
|
2022-04-01 |
2024-11-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
AR129062A1
(es)
|
2022-04-13 |
2024-07-10 |
Genentech Inc |
Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
|
|
CN119013300A
(zh)
|
2022-04-13 |
2024-11-22 |
豪夫迈·罗氏有限公司 |
抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
CA3255838A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
MULTISPECIFIC ANTIBODIES TARGETTING IL-13 AND IL-18
|
|
JP7544986B2
(ja)
|
2022-04-26 |
2024-09-03 |
中外製薬株式会社 |
医薬製剤含有フィルター内蔵シリンジ
|
|
CN119137157A
(zh)
|
2022-05-03 |
2024-12-13 |
基因泰克公司 |
抗Ly6E抗体、免疫缀合物及其用途
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20250340668A1
(en)
|
2022-05-11 |
2025-11-06 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
AU2023269545A1
(en)
|
2022-05-12 |
2024-11-14 |
BioNTech SE |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3257348A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
CN119654338A
(zh)
|
2022-06-04 |
2025-03-18 |
再生元制药公司 |
白细胞介素-2蛋白质原及其用途
|
|
EP4538294A1
(en)
|
2022-06-06 |
2025-04-16 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
|
|
WO2023246885A1
(zh)
|
2022-06-23 |
2023-12-28 |
江苏恒瑞医药股份有限公司 |
特异性结合dll3和cd3的抗原结合分子及其医药用途
|
|
JP2025523020A
(ja)
|
2022-07-13 |
2025-07-17 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
JP2025523031A
(ja)
|
2022-07-15 |
2025-07-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの処置のための結合性分子
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
AR129991A1
(es)
|
2022-07-22 |
2024-10-23 |
Bristol Myers Squibb Co |
Anticuerpos que se unen a la pad4 humana y usos de los mismos
|
|
AR129995A1
(es)
|
2022-07-22 |
2024-10-23 |
Genentech Inc |
Moléculas de unión al antígeno anti-steap1 y sus usos
|
|
AU2023312905A1
(en)
|
2022-07-27 |
2025-01-16 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
JP2025528752A
(ja)
|
2022-07-29 |
2025-09-02 |
アレクトル エルエルシー |
トランスフェリン受容体抗原結合ドメイン及びその使用法
|
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
EP4565597A2
(en)
|
2022-08-03 |
2025-06-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
AU2023318755A1
(en)
|
2022-08-03 |
2025-02-13 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
CN119546645A
(zh)
|
2022-08-05 |
2025-02-28 |
江苏恒瑞医药股份有限公司 |
特异性结合gucy2c和cd3的抗原结合分子及其医药用途
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
KR20250048583A
(ko)
|
2022-08-18 |
2025-04-09 |
리제너론 파아마슈티컬스, 인크. |
인터페론 전구단백질 및 이의 용도
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
|
JP2025535203A
(ja)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
KR20250067128A
(ko)
|
2022-09-15 |
2025-05-14 |
아비디큐어 아이피 비.브이. |
Nk 세포의 종양-표적화를 위한 다중특이적 항원 결합 단백질 및 이의 용도
|
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
JP2025533849A
(ja)
|
2022-10-07 |
2025-10-09 |
ジェネンテック， インコーポレイテッド |
抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体を用いてがんを処置する方法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
CN115724975A
(zh)
|
2022-10-20 |
2023-03-03 |
江苏荃信生物医药股份有限公司 |
抗人白介素36受体单克隆抗体及其应用
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
WO2024094017A1
(zh)
|
2022-11-01 |
2024-05-10 |
上海齐鲁制药研究中心有限公司 |
一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
|
|
JP2025537529A
(ja)
|
2022-11-02 |
2025-11-18 |
ジェンマブ エー／エス |
リヒター症候群を治療するためのｃｄ３およびｃｄ２０に対する二重特異性抗体
|
|
CN120152989A
(zh)
|
2022-11-03 |
2025-06-13 |
豪夫迈·罗氏有限公司 |
抗cd19/抗cd28双特异性抗体的组合疗法
|
|
JP2025537197A
(ja)
|
2022-11-08 |
2025-11-14 |
ジェネンテック， インコーポレイテッド |
小児期発症特発性ネフローゼ症候群を治療するための組成物および方法
|
|
JP2025539040A
(ja)
|
2022-11-10 |
2025-12-03 |
イムビア インク |
Ｄｒ５及びｍｕｃ１６に結合する細胞毒性二重特異性抗体、並びにその使用
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4619427A1
(en)
|
2022-11-15 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Recombinant binding proteins with activatable effector domain
|
|
JP2025539760A
(ja)
|
2022-11-15 |
2025-12-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合分子
|
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
CN120225684A
(zh)
|
2022-11-23 |
2025-06-27 |
豪夫迈·罗氏有限公司 |
用于增加重组蛋白表达的方法
|
|
CN120265651A
(zh)
|
2022-11-25 |
2025-07-04 |
中外制药株式会社 |
用于生产蛋白质的方法
|
|
WO2024114676A1
(zh)
|
2022-11-29 |
2024-06-06 |
江苏恒瑞医药股份有限公司 |
Cldn18.2/4-1bb结合蛋白及其医药用途
|
|
EP4631974A1
(en)
|
2022-12-08 |
2025-10-15 |
Nanjing Vazyme Biotech Co., Ltd. |
Antibody specifically binding to rsv
|
|
EP4634397A1
(en)
|
2022-12-12 |
2025-10-22 |
Genentech Inc. |
Optimizing polypeptide sialic acid content
|
|
EP4385999A1
(en)
|
2022-12-14 |
2024-06-19 |
ModiQuest B.V. |
Antibodies
|
|
JP2025541200A
(ja)
|
2022-12-15 |
2025-12-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がん処置のための併用療法
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
EP4638729A1
(en)
|
2022-12-23 |
2025-10-29 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
AU2024207469A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2024151978A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
IL321951A
(en)
|
2023-01-18 |
2025-09-01 |
Genentech Inc |
Multispecific antibodies and their uses
|
|
WO2024153725A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
EP4655315A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Payload-bearing multispecific antibodies
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
TW202436339A
(zh)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
|
|
WO2024165454A1
(en)
|
2023-02-06 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Combination therapy and uses thereof
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024175031A1
(zh)
|
2023-02-21 |
2024-08-29 |
江苏恒瑞医药股份有限公司 |
Il-36r结合蛋白及其医药用途
|
|
EP4669669A1
(en)
|
2023-02-21 |
2025-12-31 |
Teneobio, Inc. |
C-KIT BINDING PROTEINS, CHIMERIC ANTIGENIC RECEPTORS AND THEIR USES
|
|
WO2024179470A1
(zh)
|
2023-02-27 |
2024-09-06 |
苏州盛迪亚生物医药有限公司 |
抗dll3抗体、其抗体-药物偶联物及其医药用途
|
|
KR20250166361A
(ko)
|
2023-02-28 |
2025-11-27 |
리제너론 파아마슈티컬스, 인크. |
Mhc 도메인 및 항원 펩티드를 포함하는 펩티드-mhc 착물 및 면역 세포 항원 표적화 모이어티를 포함하는 다중특이적 분자
|
|
KR20250156759A
(ko)
|
2023-02-28 |
2025-11-03 |
리제너론 파아마슈티컬스, 인크. |
다가 항스파이크 단백질 결합 분자 및 이의 용도
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
CN120858109A
(zh)
|
2023-03-10 |
2025-10-28 |
基因泰克公司 |
与蛋白酶的融合物及其用途
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
CN121263449A
(zh)
|
2023-03-21 |
2026-01-02 |
拜格拉夫55公司 |
Cd19/cd38多特异性抗体
|
|
TW202446789A
(zh)
|
2023-03-31 |
2024-12-01 |
美商建南德克公司 |
抗αｖβ８整合素抗體及使用方法
|
|
EP4688841A1
(en)
|
2023-04-03 |
2026-02-11 |
F. Hoffmann-La Roche AG |
All-in-one agonistic antibodies
|
|
EP4688840A1
(en)
|
2023-04-03 |
2026-02-11 |
F. Hoffmann-La Roche AG |
Agonistic split antibodies
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024208898A1
(en)
|
2023-04-05 |
2024-10-10 |
Genmab A/S |
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
|
|
EP4687996A1
(en)
|
2023-04-05 |
2026-02-11 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
EP4442275A1
(en)
|
2023-04-06 |
2024-10-09 |
ModiQuest B.V. |
Anti-type ii collagen antibodies
|
|
WO2024213040A1
(zh)
|
2023-04-11 |
2024-10-17 |
浙江博锐生物制药有限公司 |
抗ror1抗体及其药物偶联物
|
|
TW202504915A
(zh)
|
2023-04-13 |
2025-02-01 |
丹麥商珍美寶股份有限公司 |
以抗ｃｄ３及ｃｄ２０之雙特異性抗體治療淋巴瘤之方法
|
|
JPWO2024214811A1
(sl)
|
2023-04-14 |
2024-10-17 |
|
|
|
CN121263210A
(zh)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
|
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
WO2024233926A1
(en)
|
2023-05-10 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US20240376229A1
(en)
|
2023-05-12 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
CN121285385A
(zh)
|
2023-05-12 |
2026-01-06 |
金麦安博股份有限公司 |
能够与ox40结合的抗体、其变体及其用途
|
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
|
AU2024275646A1
(en)
|
2023-05-24 |
2025-11-13 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
AR132805A1
(es)
|
2023-06-01 |
2025-07-30 |
Hoffmann La Roche |
Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
WO2024258785A1
(en)
|
2023-06-11 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
WO2024258870A2
(en)
|
2023-06-12 |
2024-12-19 |
Amgen Inc. |
Lymphotoxin beta receptor agonist binding proteins
|
|
WO2024256623A1
(en)
|
2023-06-16 |
2024-12-19 |
Heidelberg Immunotherapeutics Gmbh |
Novel anti-hsv antibody
|
|
AU2024311339A1
(en)
|
2023-06-21 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
CN121443309A
(zh)
|
2023-06-22 |
2026-01-30 |
基因泰克公司 |
多发性骨髓瘤的治疗
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025006529A1
(en)
|
2023-06-27 |
2025-01-02 |
Amgen Inc. |
Charge pair mutations to enable correct heavy-light chain pairing
|
|
WO2025007037A1
(en)
|
2023-06-28 |
2025-01-02 |
Dragonfly Therapeutics, Inc. |
Variant il-2 proteins
|
|
AU2024306598A1
(en)
|
2023-06-30 |
2025-12-11 |
Genmab A/S |
Antibodies binding to fibroblast activation protein alpha and death receptor 4
|
|
WO2025010272A1
(en)
*
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
US12319747B2
(en)
|
2023-07-03 |
2025-06-03 |
Medicovestor, Inc. |
Methods of using anti-SP17 immunotherapeutics
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
TW202521576A
(zh)
|
2023-07-30 |
2025-06-01 |
美商健生生物科技公司 |
結合至突變型鈣網蛋白之分子及其用途
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
AU2024323186A1
(en)
|
2023-08-09 |
2026-01-15 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
TW202521562A
(zh)
|
2023-08-11 |
2025-06-01 |
美商默沙東有限責任公司 |
單價介白素-12(IL-12) 異二聚體Fc蛋白
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
TW202525845A
(zh)
|
2023-08-23 |
2025-07-01 |
法商賽諾菲公司 |
基於ｃｔｌａ—４之溶體降解劑及其用途
|
|
WO2025054500A2
(en)
|
2023-09-08 |
2025-03-13 |
Mlab Biosciences, Inc. |
Bifunctional proteins and uses thereof
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025059037A1
(en)
|
2023-09-11 |
2025-03-20 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025064885A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
|
|
WO2025064890A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
US12364777B2
(en)
|
2023-10-20 |
2025-07-22 |
Medicovestor, Inc. |
Homodimeric antibodies for use in treating cancers and methods of use
|
|
AR134267A1
(es)
|
2023-11-08 |
2025-12-17 |
Sanofi Sa |
Degradador lisosómico basado en cd25 y usos del mismo
|
|
TW202535956A
(zh)
|
2023-11-10 |
2025-09-16 |
美商輝瑞大藥廠 |
抗ＭＩＧＩＳ－α抗體及其使用方法
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR134356A1
(es)
|
2023-11-17 |
2026-01-07 |
Genentech Inc |
Compuestos inhibidores de mcl-1 y uso en conjugados anticuerpos-fármacos
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025113643A1
(en)
|
2023-12-01 |
2025-06-05 |
Gilead Sciences Inc. |
Anti-fap-light fusion protein and use thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025129010A1
(en)
|
2023-12-14 |
2025-06-19 |
Genentech, Inc. |
Methods of structure determination using antibodies
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025137454A1
(en)
|
2023-12-21 |
2025-06-26 |
Amgen Inc. |
Stabilizing homodimer mutations for two cell heterodimer production
|
|
TW202542177A
(zh)
|
2023-12-22 |
2025-11-01 |
瑞士商赫孚孟拉羅股份公司 |
可活化融合蛋白及使用方法
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
WO2025147696A1
(en)
|
2024-01-05 |
2025-07-10 |
Resolve Therapeutics, Llc |
Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
US12240900B1
(en)
|
2024-02-02 |
2025-03-04 |
Medicovestor, Inc. |
Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
|
|
US12378314B1
(en)
|
2024-02-02 |
2025-08-05 |
Medicovestor, Inc. |
Proteins that bind folate receptor alpha including fully-human antibodies
|
|
US12258396B1
(en)
|
2024-02-02 |
2025-03-25 |
Medicovestor, Inc. |
Methods of using immunotherapeutics that bind folate receptor alpha
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191137A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of trop2-specific antigen binding proteins and cytokines
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
US20250313641A1
(en)
|
2024-04-09 |
2025-10-09 |
Amgen Inc. |
Agonistic anti-il-2rbg heavy-chain antibodies
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025233431A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
|
|
WO2025233304A1
(en)
|
2024-05-08 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|
|
WO2025255340A2
(en)
|
2024-06-05 |
2025-12-11 |
Genzyme Corporation |
BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
|
|
WO2025253337A2
(en)
|
2024-06-05 |
2025-12-11 |
Sanofi |
Monospecific and bispecific tau binding proteins and compositions thereof
|
|
US20250376536A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20250376524A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2025257181A1
(en)
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
CN121135878A
(zh)
|
2024-06-14 |
2025-12-16 |
康诺亚生物医药科技（成都）有限公司 |
针对ox40l和il-13的双特异性抗体及其用途
|
|
WO2025264572A1
(en)
|
2024-06-17 |
2025-12-26 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
WO2025261943A1
(en)
|
2024-06-18 |
2025-12-26 |
F. Hoffmann-La Roche Ag |
Anti-cancer combinations comprising mosperafenib and folfox or folfiri
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|